Many preclinical studies have shown that blocking TGF-β signaling is an effective anti-tumor treatment that can reduce Treg-mediated immunosuppression, increase CD8+ T cell cytotoxicity, promote T cell penetration into the center of the tumor, and thus contribute to strong anti-tumor immunity and tumor regression (55). This evidence concerns the gene TGFB1 and neoplasm.